Oblimersen and Gemtuzumab Ozogamicin in Treating Older Patients With Relapsed Acute Myeloid Leukemia

Completed · Phase 2

Conditions studied: Leukemia

In brief

RATIONALE: Monoclonal antibodies such as gemtuzumab ozogamicin can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Oblimersen may help gemtuzumab ozogamicin kill more cancer cells by making cancer cells more sensitive to the drug. PURPOSE: Phase II trial to study the effectiveness of combining oblimersen and gemtuzumab ozogamicin in treating older patients who have relapsed acute myeloid leukemia.

Key facts

Study ID

NCT00017589

Run by

Genta Incorporated

Starts

2000-12-01

Expected to finish

2006-05-01

Last updated by the study team

2014-01-06

Who can join

Age: 60 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Genta Incorporated — Berkeley Heights, New Jersey, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.